DSpace Collection: http://hdl.handle.net/10174/29502 2026-04-04T01:01:45Z 2026-04-04T01:01:45Z AI-driven tools for non-invasive skin analysis: A study in detecting lentigines and nevi in human skin Silva, Pedro Silva, Liliana Vieira, Pedro Pinto, Pedro http://hdl.handle.net/10174/41340 2026-02-20T11:57:46Z 2025-03-31T23:00:00Z Title: AI-driven tools for non-invasive skin analysis: A study in detecting lentigines and nevi in human skin Authors: Silva, Pedro; Silva, Liliana; Vieira, Pedro; Pinto, Pedro Abstract: This study demonstrates that deep learning models, particularly YOLOv4 and Faster R-CNN, can effectively detect and segment facial hyperpigmentation with high accuracy. The integration of classical image processing and a user-friendly GUI makes the system accessible to clinicians and researchers. These results highlight the potential of AI to enhance dermatological diagnostics and support longitudinal skin health monitoring. 2025-03-31T23:00:00Z Pharmacogenomic Biomarkers as a Source of evidence for Effectiveness and Safety in Alzheimer’s Disease Therapy Silva, Ana Paula Perdigão, Margarida Espírito Santo, Margarida Advinha, Ana Margarida http://hdl.handle.net/10174/41161 2026-02-13T15:28:02Z 2024-01-01T00:00:00Z Title: Pharmacogenomic Biomarkers as a Source of evidence for Effectiveness and Safety in Alzheimer’s Disease Therapy Authors: Silva, Ana Paula; Perdigão, Margarida; Espírito Santo, Margarida; Advinha, Ana Margarida Abstract: Pharmacogenomic Biomarkers as a Source of evidence for Effectiveness and Safety in Alzheimer’s Disease Therapy 2024-01-01T00:00:00Z Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024 Costa, Paula Advinha, Ana Margarida Oliveira-Martins, Sofia http://hdl.handle.net/10174/41160 2026-02-13T15:24:57Z 2025-01-01T00:00:00Z Title: Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024 Authors: Costa, Paula; Advinha, Ana Margarida; Oliveira-Martins, Sofia Abstract: Managed Entry Agreements (MEAs) are tools designed to reduce clinical uncertainty and mitigate budget impact of often high-cost, innovative medicines. While finance-based MEAs have been widely used, the increasing complexity of therapies has driven the adoption of more sophisticated and tailored agreements, including risk-sharing models. This study aims to characterize the MEAs established to support public coverage decisions for innovative medicines—defined as those containing new active substances—that received marketing authorization between 2014 and 2024 and obtained positive reimbursement decisions in Portugal. 2025-01-01T00:00:00Z Portuguese Global Medicines Access Index 2022: Intercalary Study Oliveira-Martins, Sofia Advinha, Ana Margarida http://hdl.handle.net/10174/41158 2026-02-13T15:24:30Z 2024-01-01T00:00:00Z Title: Portuguese Global Medicines Access Index 2022: Intercalary Study Authors: Oliveira-Martins, Sofia; Advinha, Ana Margarida Abstract: Portuguese Global Medicines Access Index 2022: Intercalary Study 2024-01-01T00:00:00Z